A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus Calmette-Gu&#233;rin (BCG) in Participants with BCG-na&#239;ve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)